Menu

Niagen Bioscience, Inc. NAGE

Full chart Compare
Set alert

Price alert · NAGE

All alert types
2.07 USD -0.04 (-1.66%)

At closeNov 6, 2026, 7:25 PM EST

2.10 +0.03 +1.37%

After hours · Nov 6, 7:25 PM ET

2.04 Day range 2.11
2.07 52-week range 7.18
YTD
-67.45%
1 year
-68.64%
Market cap
163.94M
Revenue (ttm)
107.92M
Profit margin
13.07%
EPS (ttm)
0.12
Shares out
78.77M
P/E ratio
17.25
YTD return
-67.45%
1-year return
-68.64%
Volume
601.51K
Avg volume
508.62K
Open
2.06
Previous close
2.11
Day's range
2.04 – 2.11
52-week range
2.07 – 7.18
Beta
2.08
Price target
14.90 (+619.8%)
Earnings date
Aug 6, 2025

1Y -4.77 (-69.74%)

246Nov 25Jan 26Feb 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 262.07

Key statistics

Enterprise value
1.09B
PEG ratio
0.00
Price / sales
9.19
Price / book
17.89
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
37.60%
Free cash flow
15.43M
Total cash
55.46M
Total debt
3.52M
Return on equity
33.47%
Short % of float
6.33%
50-day average
10.88
200-day average
7.00

Financials — quick view

All financials
NAGE Revenue — quarterly 29.79M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NAGE Net income — quarterly 963.00K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NAGE EPS — quarterly 0.01
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

NAGE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 6, 2025Jun 1, 20250.02———
May 7, 2025Mar 1, 20250.020.04+0.02+100.00%

Upgrades / downgrades

NAGE analyst upgrades and downgrades
DateFirmActionFromTo
Jun 10, 2025Canaccord GenuitymainBuyBuy
Jun 6, 2025Roth CapitalmainBuyBuy
May 27, 2025Canaccord Genuityinit—Buy
Apr 8, 2025HC Wainwright & Co.reitBuyBuy
Mar 31, 2025HC Wainwright & Co.reitBuyBuy
Mar 17, 2025HC Wainwright & Co.reitBuyBuy

About Niagen Bioscience, Inc.

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on NAGE — it syncs with the Stock Master app.

Insider holders

NAGE insider holders
InsiderRelationLatest transactionDateShares held
CHAMPION RIVER VENTURES, LTD.Director and Beneficial Owner of more than 10% of a Class of SecurityPurchaseSep 5, 20230
CHAU HOI SHUEN SOLINA HOLLYBeneficial Owner of more than 10% of a Class of SecurityPurchaseAug 19, 20240
FRIED ROBERT N.Chief Executive OfficerConversion of Exercise of derivative securityApr 8, 20251,646,730
GERBER BRIANNAChief Financial OfficerPurchaseNov 30, 202328,674
JAKSCH FRANK LOUIS JRDirectorSaleDec 12, 20242,319,230
LI KA SHINGBeneficial Owner of more than 10% of a Class of SecuritySaleAug 19, 20240

Institution ownership

NAGE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.4.59%3,617,07145.56MMar 30, 2025
Vanguard Group Inc4.49%3,540,66344.59MMar 30, 2025
Tieton Capital Management, LLC2.52%1,986,04025.01MMar 30, 2025
Shaw D.E. & Co., Inc.1.63%1,283,79016.17MMar 30, 2025
Geode Capital Management, LLC1.50%1,179,21714.85MMar 30, 2025
Arrowstreet Capital, Limited Partnership1.26%989,87312.47MMar 30, 2025

Fund ownership

NAGE fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.70%2,123,41526.74MMar 30, 2025
iShares Trust-iShares Russell 2000 ETF1.59%1,252,08915.77MApr 29, 2025
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.04%819,37610.32MMar 30, 2025
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.64%500,4126.30MApr 29, 2025
iShares Trust-iShares Russell 2000 Growth ETF0.56%442,7695.58MApr 29, 2025
Invesco Exch-Trd Fd. TRT II-Invesco Dorsey Wright SmallCap Momentum ET0.41%325,6354.10MApr 29, 2025